Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer

Breast Cancer Research and Treatment

Volumn 85, Issue 1, 2004, Pages 13-22

  Van Den Eynden, G G ^a,b,f   Van Der Auwera, I ^a,b   Van Laere, S ^a,b   Colpaert, C G ^a,b   Van Dam, P ^a,b   Merajver, S ^c   Kleer, C G ^d   Harris, A L ^e   Van Marck, E A ^a,b   Dirix, L Y ^a,b   Vermeulen, P B ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b SINT AUGUSTINUS HOSPITAL   (Belgium)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Carbonic anhydrase IX; Differential protein expression; E Cadherin; Epidermal growth factor receptor; Estrogen receptor; HER2 neu; Immunohistochemistry; Inflammatory breast cancer; P53; Progesterone receptor; RhoC GTPase; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY BREAST CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; VALIDATION PROCESS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; PROTEIN BIOSYNTHESIS; PROTEINS;

EID: 12144286354     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000021028.33926.a8     Document Type: Article

References (37)

1. Kleer GC, van Golen KL, Merajver SD: Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2: 423-429, 2000
2. Cristofanilli M, Buzdar AU, Hortobagyi GN: Update on the management of inflammatory breast cancer. Oncologist 8: 141-148, 2003
3. Koh EH, Buzdar AU, Ames FC, Singletary SE, McNeese MD, Frye D, Holmes FA, Fraschini G, Hug V, Theriault RL et al.: Inflammatory carcinoma of the breast: results of a combined-modality approach - M.D. Anderson Cancer Center experience. Cancer Chemother Pharmacol 27: 94-100, 1990
4. Jaiyesimi IA, Buzdar AU, Hortobagyi G: Inflammatory breast cancer: a review. J Clin Oncol 10: 1014-1024, 1992
5. Paradiso A, Tommasi S, Brandi M, Marzullo F, Simone G, Lorusso V, Mangia A, De Lena M: Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 64: 1922-1927, 1989
6. Robertson JF, Ellis IO, Pearson D, Elston CW, Nicholson RI, Blarney RW: Biological factors of prognostic significance in locally advanced breast cancer. Breast Cancer Res Treat 29: 259-264, 1994
7. Turpin E, Bieche I, Bertheau P, Plassa LF, Lerebours F, de Roquancourt A, Olivi M, Espie M, Marty M, Lidereau R, Vidaud M, de The H: Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene 21: 7593-7597, 2002
8. Kaufmann M: Review of known prognostic variables. Recent Results Cancer Res 140: 77-87, 1996
9. Guerin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G: Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer 43: 201-208, 1989
10. Charpin C, Bonnier P, Khouzami A, Vacheret H, Andrac L, Lavaut MN, Allasia C, Piana L: Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Anticancer Res 12: 591-597, 1992
11. Hahnel R, Twaddle E: Estrogen receptors in human breast cancer. 1. Methodology and characterization of receptors. Steroids 18: 653-680, 1971
12. Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF, Livant D, Merajver SD: WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 21: 3172-3180, 2002
13. van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD: A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 5: 2511-2519, 1999
14. Alpaugh ML, Tomlinson JS, Kasraeian S, Barsky SH: Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene 21: 3631-3643, 2002
15. Kleer CG, van Golen KL, Braun T, Merajver SD: Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 14: 458-464, 2001
16. Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD: Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 160: 579-584, 2002
17. Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, Goovaerts G, Dirix LY, van Dam P, Fox SB, Harris AL, van Marck EA: Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer 88: 718-725, 2003
18. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998
19. Sauter G, Mirlacher M: Tissue microarrays for predictive molecular pathology. J Clin Pathol 55: 575-576, 2002
20. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159: 2249-2256, 2001
21. Sapino A, Coccorullo Z, Cassoni P, Ghisolfi G, Gugliotta P, Bongiovanni M, Arisio R, Crafa P, Bussolati G: Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains. Histopathology 43: 354-362, 2003
22. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 33: 159-174, 1977
23. Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998
24. Bergers E, van Diest PJ, Baak JP: Tumour heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry. J Clin Pathol 49: 931-937, 1996
25. Braun S, Hepp F, Sommer HL, Pantel K: Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer 84: 1-5, 1999
26. Geyer H, Eberl M, Hornberger B: Influence of tissue heterogeneity on the determination of steroid receptors in breast cancer. J Cancer Res Clin Oncol 110: 141-144, 1985
27. Osborne CK: Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol 12: 317-326, 1985
28. Paradiso A, Mangia A, Barletta A, Fusilli S, Marzullo F, Schittulli F, De Lena M: Heterogeneity of intratumour proliferative activity in primary breast cancer: biological and clinical aspects. Eur J Cancer 31A: 911-916, 1995
29. Poulsen HS, Jensen J, Hermansen C: Human breast cancer: heterogeneity of estrogen binding sites. Cancer 48: 1791-1793, 1981
30. Symmans WF, Liu J, Knowles DM, Inghirami G: Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol 26: 210-216, 1995
31. Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo D, Brennan MF, Lewis JJ, Cordon-Cardo C: Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 158: 1245-1251, 2001
32. Zhang D, Salto-Tellez M, Puni TC, Do E, Koay ES: Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16: 79-85, 2003
33. Camp RL, Charette LA, Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest 80: 1943-1949, 2000
34. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD: RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60: 5832-5838, 2000
35. van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD: RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2: 418-425, 2000
36. Beavon IR: Regulation of E-cadherin: does hypoxia initiate the metastatic cascade? Mol Pathol 52: 179-188, 1999
37. Beavon IR: The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer 36: 1607-1620, 2000